RT Journal Article
SR Electronic
T1 Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3945
OP 3947
DO 10.21873/anticanres.13547
VO 39
IS 7
A1 MARJANSKA, AGATA
A1 GALAZKA, PRZEMYSLAW
A1 MARJANSKI, MICHAL
A1 WYSOCKI, MARIUSZ
A1 STYCZYNSKI, JAN
YR 2019
UL http://ar.iiarjournals.org/content/39/7/3945.abstract
AB Background/Aim: Malignant melanoma is a rare disease in the pediatric population and there are no recommendations regarding its management in children, while the current standard of care in metastatic or unresectable melanoma in adult patients includes immunotherapy (anti-CTLA-4 and anti-PD-1 antibodies). Advances in the management of adults with melanoma offer the prospect of promising therapeutic options for children. Case Report: We describe a case of a 7-year-old patient with recurrent metastatic melanoma, for whom pembrolizumab was used as an adjuvant therapy on compassionate use basis. Conclusion: Due to adverse events, the treatment was discontinued after 5 months of pembrolizumab, but with 12-months of follow-up, patient remains in complete remission.